Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...

We have these four representatives here. Hello, everyone. I am Atsushi Kitamura from Astellas Pharma Inc. Thank you very much for joining our FY 2024 third quarter year-to-date financial results ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Astellas Pharma Inc., a global life sciences company committed to turning innovative science into VALUE for patients, announced the submission of a New Drug Application (NDA) to Japan’s Ministry of ...

Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking conditional approval of avacincaptad pegol intravitreal solution (ACP ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...